Analyst Coverage

The following research analysts cover Destiny Pharma.

Mark Brewer, finnCap	+44(0)20 7220 0500
Andy Smith, Equity Development	+44(0)20 7065 2690

Please click on links below to access coverage published:

	finnCap Analyst research from finnCap can be obtained by registering on the link above 17 September 2020 – Interims – on track for Q1 2021 Phase 2b readout 7 September 2020 – Co-development collaboration and Innovate UK grant
	Equity Development 11 December 2020 – Interview with Neil Clark, CEO 27 November 2020 – Competition for XF-73 moves aside, issue approved
	Proactive Investors For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above